NEW #podcast episode: 'Updates in #immunotherapy for #skincancer’ 🎧 In this episode we cover: 🔦 Impact of T-Cell therapies, such as #lifileucel, in patients with #melanoma 🔦 Results of the 7-year CheckMate 238 trial (NCT02388906) of #nivolumab 🔦 Effective #sequencing of treatments in the #SECOMBITtrial (NCT02631447) 🔦 Challenges in managing immunotherapy related #adverseevents With leading experts: 🌟 Omid Hamid, MD, The Angeles Clinic & Research Institute, Inc. 🌟 Paolo A. Ascierto, MD, IRCCS Istituto Nazionale Tumori Fondazione G Pascale, Napoli, Italy 🌟 Georgina Long, PhD, MBBS, FRACP, FAHMS, Medicine and Health - University of Sydney 🌟 Karijn Suijkerbuijk, MD, PhD, UMC Utrecht Give it a listen 👉https://lnkd.in/eqnYMHRa Use the time codes to skip to your favourite part of each episode 👀 SUBSCRIBE so you don't miss any future episodes📱 #VJOncology
Video Journal of Oncology (VJOncology)
Hospitals and Health Care
Oxford, Oxfordshire 1,124 followers
A global, open-access video journal focussed on Oncology
About us
The Video Journal of Oncology (VJOncology) is an independent global open access video journal, dedicated to providing trusted and up-to-date information in order to improve knowledge, understanding, and awareness of oncology. Our goal is to expedite learning through the sharing of new data and expert opinion, and to rapidly disseminate the latest news and information to healthcare professionals, worldwide, on a range of innovative digital media – including video and blog formats. VJOncology content is led by an editorial board of highly respected thought leaders with a combined expertise that spans the spectrum of oncology. All content will be created and published under the guidance of this board of world-leading experts.
- Website
-
http://www.vjoncology.com/
External link for Video Journal of Oncology (VJOncology)
- Industry
- Hospitals and Health Care
- Company size
- 11-50 employees
- Headquarters
- Oxford, Oxfordshire
- Type
- Privately Held
- Founded
- 2016
- Specialties
- Video, Oncology, Conference, News, Publishing, Journal, Medical Education, and Cancer
Locations
-
Primary
Magdalen Centre
The Oxford Science Park
Oxford, Oxfordshire OX4 4GA, GB
Updates
-
Check out our NEW #podcast episode: #iwCAR-T sessions: Advances in #breast and #gynecological cancers 🎧 In this episode, we join experts: 🌟 Jennifer Specht, Fred Hutchinson Cancer Center 🌟 Saurabh Garg, Moffitt Cancer Center 🌟 Rizwan Romee, Dana-Farber Cancer Institute They discuss pioneering advancements in #CARTcell therapies for #breast and #gynecologicalcancers, as discussed at the recent 6th annual iwCAR-T workshop in Miami, Florida 🇺🇸 Tune in to learn about the fascinating evolution of #ROR1-targeting CAR-T cells for #triplenegativebreastcancer, NK-cell targeting CAR-T therapeutics in #ovariancancer, and combinatorial therapy using #dendriticcells against #HER2-positive #breastcancer As their development progresses, several challenges and advantages come to light 🔦 Give it a listen 👉 https://lnkd.in/evmYJQXP Use the time codes to skip to your favourite part of each episode 👀 SUBSCRIBE so you don't miss any future episodes📱 #VJOncology #BCsm
-
-
NEW from #ASCO2024 | SURE-01/02: #sacituzumab #govitecan and #pembrolizumab for #MIBC 🎥 🇺🇸 Antonio Cigliola, MD, IRCCS San Raffaele Hospital, discusses the findings from the SURE-01/02 trial (NCT05226117) investigating the #antibodydrugconjugate (ADC) #sacituzumabgovitecan (SG) alone or in combination with #pembroluzimab, for patients with muscle-invasive #bladdercancer (MIBC) 🔦 The study was carried out in patients who refused or were ineligible for #cisplatin-based #chemotherapy 🌟 A majority of patients completed four rounds of SG, and pathological complete response (pCR) was seen in nearly half of patients who did not receive a radical #cystectomy 🌟 Learn more 👉 https://lnkd.in/dudzS_3y #VJOncology #Oncologynews
-
JULY is #Sarcoma Awareness Month 📣 💡 Check out this video from #AACR2024 | CCNG1 as a #biomarker for DRG-101 gene therapy in #cancer 🎥 Vaishali Kumar, MBBS, Sarcoma Oncology Research Center, discusses findings from an analysis of #CCNG1 expression in 137 patients across various #cancer types treated with DRG-101, a #tumor-targeted retrovector 🌟 All tumors exhibited enhanced #CCNG1expression, with varying levels across patients 🌟 Notably, patients with sustained #remission from #metastatic #pancreaticcancer and #breastcancer showed specific CCNG1 expression levels 🌟 DRG-101 additionally has potential in #combinationtherapy for advanced #pancreaticcancer, #sarcoma, and #breastcarcinoma Learn more 👉 https://lnkd.in/emURYRSA #VJOncology #Oncologynews #SarcomaAwarenessMonth
CCNG1 as a biomarker for DRG-101 gene therapy in cancer - VJOncology
https://www.vjoncology.com
-
Check out our NEW #podcast episode: #iwCAR-T sessions: #clinical advances in #lungcancer 🎧 In this episode, we dive into cutting-edge #CARTcell therapies for the management of #lungcancers, discussed at the sixth International Workshop on CAR-T in Miami, Florida 🫁 🇺🇸 With leading experts: 🌟 Julian Molina, Mayo Clinic 🌟 Ben Creelan, Moffitt Cancer Center 🌟 Adam Schoenfeld, Memorial Sloan Kettering Cancer Center They address the challenges of integrating #celltherapies in #clinical practice, the potential for #tumor cell banking, and the implications of tumor #microenvironment modulation This episode provides a comprehensive overview of the future landscape of #celltherapy in #lungcancer treatment 💡 Give it a listen 👉 https://lnkd.in/eNk86tJv Use the time codes to skip to your favourite part of each episode 👀 SUBSCRIBE so you don't miss any future episodes📱 #VJOncology #CRCsm
-
-
NEW from #ESMOGI2024 | NEST-1: #neoadjuvant #botensilimab and #balstilimab in #colorectalcancer 🎥 🇩🇪 Juan Manuel O´Connor, MD, MSc, IAF (Instituto Alexander Fleming), discusses the Phase II NEST-1 trial (NCT05571293) of neoadjuvant #botensilimab, a #CTLA4inhibitor, plus #balstilimab, a #PD1inhibitor, in patients with #resectable #colorectalcancer #Pathologic responses were promising in patients, especially in patients with microsatellite instability-high (MSI-H) #tumors. The study supports further exploration of #immunotherapy duration and watch-and-wait strategies for MSI-H patients 🔦 Learn more 👉 https://lnkd.in/e_F3p3ys #VJOncology #Oncologynews #CRCsm
NEST-1: neoadjuvant botensilimab and balstilimab in colorectal cancer - VJOncology
https://www.vjoncology.com
-
NEW from #ESMOGI2024 | Safety concerns of using #HER2-targeting therapies in #gastrointestinalcancers 🎥 🇩🇪 Sara Lonardi, MD, Veneto Institute of Oncology, addresses safety considerations when utilizing #HER2-directed therapies in #gastrointestinalcancers While rare, there is a risk of developing interstitial #lungdisease (ILD) with #trastuzumab #deruxtecan 💡 Prompt recognition of grade 1 toxicity symptoms is crucial, following clinical guidelines that recommend discontinuing treatment until ILD resolves to grade 0, followed by corticosteroids 💡 Escalation to grade 2 toxicity necessitates discontinuation of trastuzumab deruxtecan 💡 Managing other toxicity symptoms such as nausea and vomiting with anti-emetic medications is feasible, but maintaining the balance between symptom relief and preserving the efficacy of anticancer treatment remains pivotal Learn more 👉 https://lnkd.in/eDMaNa5X #VJOncology #Oncologynews
Safety concerns of using HER2-targeting therapies in gastrointestinal cancers - VJOncology
https://www.vjoncology.com
-
Video Journal of Oncology (VJOncology) reposted this
🚀 Launching our new website! 🚀 🎉 Magdalen Medical Publishing is proud to present our new platform dedicated to medical events, Magdalen Scientific. 🎥 With established video journals like Video Journal of Hematology & Hematological Oncology (VJHemOnc), Video Journal of Oncology (VJOncology) and Video Journal of Neurology (VJNeurology), we bring the same level of excellence to our events. Discover more about our events and how to partner with us, by visiting our new website: magdalenscientific.com #MagdalenScientific #IME #HCPEducation #scientificworkshops #educationalwebinars #VJHemOnc #VJOncology #VJNeurology
Independent, Expert-led Scientific Events
magdalenscientific.com
-
Today is #Glioblastoma Awareness Day (GBM Day) 📣 💡 Check out this video from #AACR2024 | Challenges in #glioblastoma treatment: #bortezomib trial for improved outcomes 🎥 Martha Chekenya, PhD, University of Bergen, discusses the challenges of treating #glioblastoma, the most common #malignant #braintumor in adults, with a poor prognosis of only about 15 months survival after diagnosis 🧠 Despite various targeted therapies and emerging #immunotherapies, responses have been limited due to high #cellular and #molecular #heterogeneity and the #blood-brain barrier’s restrictions 🩸 Prof. Chekenya highlights a Phase I/II clinical trial (NCT03643549) using #bortezomib, a #proteasomeinhibitor targeting the transcription factor NF-κB, to sensitize treatment-#refractory #glioblastoma #tumors to #temozolomide #chemotherapy This hypothesis-driven trial aims to overcome resistance mechanisms and improve treatment outcomes for patients 🔦 Learn more 👉 https://lnkd.in/e3zGGqbd #VJOncology #Oncologynews #GlioblastomaAwarenessDay
Challenges in glioblastoma treatment: bortezomib trial for improved outcomes - VJOncology
https://www.vjoncology.com
-
Today is #Glioblastoma Awareness Day (GBM Day) 📣 💡 Check out this video from #ASCO2024 | #PET vs. #MRI in re-irradiation for recurrent #glioblastoma: insights from a Phase II trial 🎥 Ilinca Popp, MD, from University Medical Center Freiburg, discusses a prospective, multicenter Phase II trial (NCT01252459) comparing FET-PET and T1Gd-MRI-based target volume delineation in re-irradiation for recurrent #glioblastoma (#rGBM) 🔦 Despite expectations, FET-PET-based treatment did not improve progression-free survival (PFS) or overall survival (OS) compared to T1Gd-MRI-based treatment Both options were deemed valid, with stereotactic re-irradiation being safe. FET-PET investigation was well tolerated, maintaining its #diagnostic role in differentiating #rGBM progression from post-therapeutic changes Dr Popp emphasizes the importance of identifying the specific patient subgroups for whom these investigations are most beneficial, noting that while #PET imaging did not alter diagnostic sensitivity or specificity, it did result in differences in target volumes compared to #MRI Learn more 👉 https://lnkd.in/d6hUq2mf #VJOncology #Oncologynews #GlioblastomaAwarenessDay
PET vs. MRI in re-irradiation for recurrent glioblastoma: insights from a Phase II trial - VJOncology
https://www.vjoncology.com